CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
BM4SIT focuses on enhancing allergen-specific immunotherapy for birch pollen allergy by using mutated recombinant allergens and an adjuvant to improve safety and efficacy. The project aims to create a treatment that minimizes side effects while effectively inducing an immune response.
Allergy is the most prevalent chronic inflammatory disease, having great socio-economic impact.
Chronic lifelong dependency on symptomatic drugs is an expensive reality for the vast majority of allergy sufferers.
Allergen-specific immunotherapy is the only causal and effective treatment targeting the underlying immune mechanism in a more cost-effective way.
Yet, long treatment duration and risk of anaphylactic side-effects have prevented this treatment from becoming the first choice. BM4SIT aims…
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Austria, Salzburg
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Netherlands, LEIDEN
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Austria, WIEN
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
